Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989950 | 0.92 | EGFR (0.47) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL25938 | 0.88 | CSNK2A1 (0.45) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL26875 | 0.87 | CSNK2A1 (0.49) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL26540 | 0.87 | DYRK1A (0.44) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL26592 | 0.85 | EGFR (0.44) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL24316 | 0.85 | AURKA (0.43) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL2991831 | 0.85 | DYRK1A (0.47) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL26636 | 0.85 | EGFR (0.47) | EGFRAURKARPS6KB1CSNK2A1DYRK1A | |
| SCHEMBL24978 | 0.85 | CSNK2A1 (0.43) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 | |
| SCHEMBL2998232 | 0.84 | EGFR (0.46) | EGFRAURKARPS6KB1CSNK2A1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ELDER JAMES T (US) | 2004-10-07 | — | — | US | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | RARB, EBP, RXRA | EGFR 47/4885AURKA 4045/4885RPS6KB1 912/4885 |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | EGFR, RARB, RXRA | EGFR 1/4885AURKA 3680/4885RPS6KB1 1462/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885AURKA 92/4885RPS6KB1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.